Is Semaglutide Legal in Canada? (2026 Research Status)

Imagine you’re a Canadian researcher investigating semaglutide’s effects on metabolic markers. You’ve reviewed the clinical literature — the landmark STEP trials and SUSTAIN program — and you want to source the compound for a new observational study. Your first question isn’t about dosing protocols or biomarkers. It’s far more basic: Can I legally obtain and work with semaglutide in Canada?

If that scenario sounds familiar, you’re not alone. The regulatory landscape surrounding semaglutide in Canada has shifted multiple times in recent years, and navigating it can feel like reading a map that keeps redrawing itself. Between Health Canada approvals, prescription scheduling, compounding pharmacy rules, and import restrictions, the picture is genuinely complex.

This guide is designed to clear up the confusion. We’ll walk through what the science says about semaglutide, how Canadian law classifies it, what recent regulatory changes mean, and where researchers and informed consumers stand in 2026.

What Is Semaglutide? The Research Context

Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist — a class of compounds that research suggests may modulate appetite signaling, gastric emptying, and glucose-dependent insulin secretion Knudsen & Lau, 2019. Originally developed for type 2 diabetes management, semaglutide became the subject of intense research interest after studies indicated it might also influence body weight through central appetite pathways.

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program generated particularly notable findings. In STEP 1, a large randomized controlled trial, participants receiving once-weekly semaglutide 2.4 mg showed greater changes in body weight compared to placebo over 68 weeks, with a mean change of approximately 14.9% from baseline Wilding et al., 2021. The STEP 2 trial extended this research to participants with type 2 diabetes and reported similar directional trends, though with somewhat more modest effect sizes Davies et al., 2021.

It’s worth noting that these are clinical trial results from controlled settings. Real-world outcomes may differ substantially depending on individual biology, adherence, and concurrent lifestyle factors. The research is promising but ongoing, and no compound — semaglutide included — should be treated as a certainty.

For a deeper dive into the compound’s pharmacology and mechanism of action, see our full semaglutide compound profile.

The Canadian Regulatory Framework

Health Canada regulates pharmaceutical drugs through the Food and Drugs Act and its associated Regulations. Semaglutide has received several distinct approvals from Health Canada, each tied to specific indications, brand formulations, and patient populations.

Approved Semaglutide Products in Canada

Ozempic (semaglutide injection, once-weekly) was first authorized by Health Canada in 2018 for the improvement of glycemic control in adults with type 2 diabetes. The indication was subsequently expanded to include cardiovascular risk reduction in certain patient populations, following evidence from the SUSTAIN 6 cardiovascular outcomes trial Marso et al., 2016.

Wegovy (semaglutide injection at higher dose for chronic weight management) received Health Canada authorization later, for use as an adjunct to reduced-calorie diet and increased physical activity in adults with obesity or overweight who have at least one weight-related comorbidity.

Rybelsus (oral semaglutide) has also been authorized in Canada for type 2 diabetes management, offering a non-injectable option that some patients may prefer.

All three products are classified as prescription drugs under Canadian law. This means they cannot be legally sold over the counter, and a licensed healthcare practitioner must authorize their use.

Prescription Requirements: What This Means in Practice

The prescription-only status of semaglutide products in Canada has several practical implications:

1. Patients can only obtain Health Canada-authorized semaglutide products (Ozempic, Wegovy, Rybelsus) through a valid prescription from a licensed Canadian physician or nurse practitioner.
2. Pharmacies — both brick-and-mortar and licensed online pharmacies — must verify a prescription before dispensing.
3. Non-prescribed possession of a prescription drug raises different legal questions than possession of a controlled substance, but selling or distributing prescription drugs without authorization remains illegal under the Food and Drugs Act.

This is a critical distinction. Semaglutide is not a controlled substance under Canada’s Controlled Drugs and Substances Act. It does not fall into the same legal category as opioids, stimulants, or anabolic steroids. Its regulation is pharmaceutical in nature, not criminal — though violations of prescription drug rules can still carry significant penalties.

For a broader discussion of how peptide-based compounds fit into the Canadian regulatory picture, our guide on peptide legality in 2026 provides useful context.

Compounding Pharmacies and Semaglutide

One area that has generated considerable confusion is compounding. Compounding pharmacies prepare customized medications for individual patients based on a practitioner’s prescription. In Canada, compounding is regulated provincially, and the rules vary from one jurisdiction to another.

Following supply shortages of brand-name semaglutide products in 2022–2024, some compounding pharmacies in Canada began preparing semaglutide formulations to fill the gap. However, Health Canada has issued guidance indicating that compounding pharmacies may only prepare semaglutide when a specific patient need exists that cannot be met by an authorized product — for example, when a patient requires an allergen-free formulation or a dosage form not commercially available.

The key points for researchers and consumers to understand:

• Compounded semaglutide is not the same as a Health Canada-authorized product. It has not undergone the same quality, safety, and efficacy review.
• Compounding is not a loophole for bulk sourcing. Provincial pharmacy regulators and Health Canada have both indicated that compounding should not be used to replicate commercially available products at scale.
• Quality assurance varies. While many compounding pharmacies operate under rigorous standards, the absence of a centralized approval process means that consistency between pharmacies may differ.

Importing Semaglutide into Canada

Another common question involves importing semaglutide from international sources. Canada’s Personal Importation provisions under the Food and Drugs Act generally permit individuals to import a limited supply of a prescription drug for personal use, provided certain conditions are met:

• The drug must be for the individual’s own use (or for a person under their direct care).
• The quantity must not exceed a 90-day supply.
• The drug must not be a controlled substance.
• A prescription or equivalent documentation from a licensed practitioner should be available.

However, enforcement practices can be inconsistent. The Canada Border Services Agency (CBSA) and Health Canada retain discretion to seize shipments that do not meet regulatory requirements. Importing semaglutide from unverified international sources — particularly from jurisdictions where pharmaceutical quality standards may differ — carries risks related to product integrity, proper storage conditions, and regulatory compliance.

Research institutions sourcing semaglutide for laboratory use typically follow different pathways, often working directly with authorized pharmaceutical distributors or through institutional procurement channels that include proper documentation and chain-of-custody protocols.

What’s Changed in 2026?

As of 2026, several developments have shaped the current landscape:

• Supply stabilization. After the shortages of 2022–2024, brand-name semaglutide products have become more consistently available in Canadian pharmacies. This has reduced — though not eliminated — reliance on compounding alternatives.
• Continued prescription-only classification. Despite periodic advocacy for over-the-counter availability of lower-dose formulations, Health Canada has maintained semaglutide’s prescription-only status.
• Ongoing research. Clinical trials continue to explore semaglutide’s potential in new areas, including cardiovascular outcomes in non-diabetic populations and combination therapies. The evidence base is expanding, but much of it remains preliminary.
• Regulatory scrutiny of compounding. Provincial pharmacy regulators have issued updated guidance on compounding standards, particularly for high-demand compounds like semaglutide.

For the latest on sourcing options available to Canadian researchers and consumers, our where-to-buy semaglutide guide covers the current market in detail.

Key Takeaways

Here’s the short version for anyone navigating semaglutide’s legal status in Canada:

• Semaglutide is a prescription drug, not a controlled substance. It’s regulated under the Food and Drugs Act, not the Controlled Drugs and Substances Act.
• Health Canada has authorized three semaglutide products (Ozempic, Wegovy, Rybelsus) for specific medical indications.
• Compounding is permitted under narrow circumstances and is regulated at the provincial level.
• Personal importation of prescription drugs is allowed under limited conditions, but carries quality and compliance risks.
• Research use follows separate procurement pathways that prioritize documentation and quality assurance.

The science around semaglutide is evolving quickly. Studies continue to investigate its effects on metabolic health, appetite regulation, and cardiovascular markers. But the legal and regulatory framework determines how — and whether — individuals can access the compound in practice. Understanding that framework is the first step toward making informed, compliant decisions.

Frequently Asked Questions

Is semaglutide a controlled substance in Canada?

No. Semaglutide is classified as a prescription drug under the Food and Drugs Act, but it is not listed under the Controlled Drugs and Substances Act. This means it doesn’t fall into the same legal category as drugs like testosterone or certain stimulants. However, it still requires a valid prescription for legal purchase and use.

Can I buy semaglutide online in Canada?

Licensed Canadian pharmacies can dispense semaglutide online, provided you have a valid prescription from a Canadian-licensed healthcare practitioner. Purchasing from unlicensed international sources carries legal and quality risks. See our buying guide for more detail on current options.

Are compounding pharmacies allowed to make semaglutide?

Provincially regulated compounding pharmacies in Canada may prepare semaglutide formulations under specific circumstances — typically when an authorized product cannot meet a particular patient’s needs. However, compounding is not intended as a substitute for commercially available products, and regulatory guidance has tightened since the supply shortages of 2022–2024.

How does Canada’s semaglutide regulation compare to the U.S.?

Both countries classify semaglutide as a prescription drug. The U.S. FDA and Health Canada have each authorized semaglutide products for similar indications, though specific approved products and labeling may differ. Compounding regulations also differ significantly between the two countries, with the U.S. operating under a distinct federal framework through the FDA’s compounding provisions.

Is research use of semaglutide legal in Canada?

Research institutions can typically procure semaglutide through authorized pharmaceutical distributors for use in approved research settings. The specific requirements depend on the nature of the research, the institution’s protocols, and applicable federal and provincial regulations. Researchers should consult their institutional review boards and procurement departments for guidance on proper sourcing and documentation.